Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: TRM003
MIFTS: 50

Tremor

Categories: Genetic diseases, Mental diseases, Muscle diseases, Neuronal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Tremor

About this section

MalaCards integrated aliases for Tremor:

Name: Tremor 53 29 6 42
Tremors 6

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Neuronal diseases Muscle diseases Oral diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

ICD10 32 R25.1
Sources

Summaries for Tremor

About this section
MedlinePlus : 42 What is a tremor? A tremor is a rhythmic shaking movement in one or more parts of your body. It is involuntary, meaning that you cannot control it. This shaking happens because of muscle contractions. A tremor is most often in your hands, but it could also affect your arms, head, vocal cords, trunk, and legs. It may come and go, or it may be constant. Tremor can happen on its own or be caused by another disorder. What are the types of tremor? There are several types of tremor, including Essential tremor, sometimes called benign essential tremor. This is the most common type. It usually affects your hands, but it can also affect your head, voice, tongue, legs, and trunk. Parkinsonian tremor, which is a common symptom in people who have Parkinson's disease. It is usually affects one or both hands when they are at rest, but it can affect the chin, lips, face, and legs. Dystonic tremor, which happens in people who have dystonia. Dystonia is a movement disorder in which you have involuntary muscle contractions. The contractions cause you to have twisting and repetitive movements. It can affect any muscle in the body. What causes tremor? Generally, tremor is caused by a problem in the deep parts of the brain that control movements. For most types, the cause is unknown. Some types are inherited and run in families. There can also be other causes, such as Neurologic disorders, including multiple sclerosis, Parkinson's disease, stroke, and traumatic brain injury Certain medicines, such as asthma medicines, amphetamines, caffeine, corticosteroids, and medicines used for certain psychiatric and neurological disorders Alcohol use disorder or alcohol withdrawal Mercury poisoning Hyperthyroidism (overactive thyroid) Liver or kidney failure Anxiety or panic Who is at risk for tremor? Anyone can get tremor, but it is most common in middle-aged and older adults. For certain types, having a family history raises your risk of getting it. What are the symptoms of tremor? Symptoms of tremor may include Rhythmic shaking in the hands, arms, head, legs, or torso Shaky voice Difficulty writing or drawing Problems holding and controlling utensils, such as a spoon How is tremor diagnosed? To make a diagnosis, your health care provider Will take your medical history Will do a physical exam, which includes checking Whether the tremor happens when the muscles are at rest or in action The location of the tremor How often you have the tremor and how strong it is Will do a neurological exam, including checking for Problems with balance Problems with speech Increased muscle stiffness May do blood or urine tests to look for the cause May do imaging tests to help figure out if the cause is damage in your brain May do tests which check your abilities to do daily tasks such as handwriting and holding a fork or cup May do an electromyogram. This is a test which measures involuntary muscle activity and how your muscles respond to nerve stimulation What are the treatments for tremor? There is no cure for most forms of tremor, but there are treatments to help manage symptoms. In some cases, the symptoms may be so mild that you do not need treatment. Finding the right treatment depends on getting the right diagnosis of the cause. Tremor caused by another medical condition may get better or go away when you treat that condition. If your tremor is caused by a certain medicine, stopping that medicine usually makes the tremor go away. Treatments for tremor where the cause is not found include Medicines. There are different medicines for the specific types of tremor. Another option is Botox injections, which can treat several different types. Surgery may be used for severe cases that do not get better with medicines. The most common type is deep brain stimulation (DBS). Physical, speech-language, and occupational therapy, which may help to control tremor and deal with the daily challenges caused by the tremor If you find that caffeine and other stimulants trigger your tremors, it may be helpful to cut them from your diet. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Tremor, also known as tremors, is related to tremor, hereditary essential, 1 and fragile x tremor/ataxia syndrome. An important gene associated with Tremor is C19orf12 (Chromosome 19 Open Reading Frame 12), and among its related pathways/superpathways is Neuroscience. The drugs Pregabalin and Propranolol have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and thalamus, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

NINDS : 53 Tremor is an unintentional, rhythmic, muscle movement involving to-and-fro movements of one or more parts of the body. Most tremors occur in the hands, although they can also affect the arms, head, face, voice, torso, and legs. Generally, tremor is caused by a problem in the deep parts of the brain that control movements.  Some forms of tremor are inherited and run in families, while others have no known cause. Sometimes tremor is a symptom of another neurological disorder or a side effect of certain drugs, but the most common form occurs in otherwise healthy people. Excessive alcohol consumption or alcohol withdrawal can kill certain nerve cells, resulting in tremor, especially in the hand. Other causes include an overactive thyroid and the use of certain drugs. Tremor may occur at any age but is most common in middle-aged and older adults. There are several types of tremor, one of the most common of which is essential tremor (sometimes called benign essential tremor). The hands are most often affected but the head, voice, tongue, legs, and trunk may also be involved. Head tremor may be seen as a "yes-yes" or "no-no" motion. Onset is most common after age 40, although symptoms can appear at any age. Parkinsonian tremor is caused by damage to structures within the brain that control movement. The tremor is classically seen as a "pill-rolling" action of the hands but may also affect the chin, face, lips, and legs. Dystonic tremor occurs in individuals of all ages who are affected by dystonia, a movement disorder which causes muscles to be over-active, resulting in abnormal postures or sustained, unwanted movements.

Wikipedia : 73 A tremor is an involuntary, somewhat rhythmic, muscle contraction and relaxation involving oscillations... more...

Sources

Related Diseases for Tremor

About this section

Diseases in the Tremor family:

Tremor, Hereditary Essential, 1 Tremor, Hereditary Essential, 2
Tremor, Hereditary Essential, 3 Tremor, Hereditary Essential, 4
Tremor, Hereditary Essential, 5 Tremor, Hereditary Essential, 6
Essential Tremor Rare Tremor Disorder

Diseases related to Tremor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 880)
# Related Disease Score Top Affiliating Genes
1 tremor, hereditary essential, 1 32.9 TENM4 FUS DRD3
2 fragile x tremor/ataxia syndrome 32.9 FRAXA FMR1
3 tremor, hereditary essential, 5 32.7 TENM4 DNAJC13
4 fragile x-associated tremor/ataxia syndrome 32.7 FUS FRAXA FMR1
5 tremor, hereditary essential, 4 32.6 TENM4 FUS DNAJC13
6 tremor, hereditary essential, 3 32.5 TENM4 FUS DRD3
7 tremor, hereditary essential, 2 32.5 TENM4 FUS ETM2 DRD3
8 essential tremor 32.0 TENM4 PRKN NOTCH2NLC LRRK2 GBA FUS
9 multiple system atrophy 1 31.8 PRKN LRRK2 FMR1
10 parkinsonism 31.7 LRRK2 LOC106627981 GBA
11 parkinson disease 1, autosomal dominant 31.6 PRKN LRRK2 GBA
12 parkinson disease 21 31.5 PRKN LRRK2 DNAJC13
13 dystonia 31.4 PRKN LRRK2 FUS DRD3 C19orf12
14 parkinson disease 15, autosomal recessive early-onset 31.3 PRKN LRRK2 C19orf12
15 parkinson disease, late-onset 31.1 PRKN LRRK2 LOC106627981 GBA FMR1 DRD3
16 kufor-rakeb syndrome 30.9 PRKN LRRK2 GBA C19orf12
17 dementia, lewy body 30.9 PRKN LRRK2 LOC106627981 GBA FUS
18 movement disease 30.8 PRKN LRRK2 LOC106627981 GBA FUS FMR1
19 fmr1 disorders 30.8 FRAXA FMR1
20 aceruloplasminemia 30.8 MT-ATP6 HARS1 C19orf12
21 cerebellar disease 30.7 PRKN FUS FMR1
22 supranuclear palsy, progressive, 1 30.7 PRKN LRRK2 GBA FUS
23 autosomal dominant cerebellar ataxia 30.7 PRKN LRRK2 FUS FMR1
24 restless legs syndrome 30.5 PRKN FRAXA FMR1 DRD3
25 rem sleep behavior disorder 30.5 PRKN LRRK2 GBA
26 speech disorder 29.9 LOC106627981 GBA FMR1
27 postencephalitic parkinson disease 29.8 PRKN LRRK2
28 amyotrophic lateral sclerosis 1 29.8 PRKN MT-ATP6 LRRK2 FUS FMR1 FIG4
29 early-onset parkinson's disease 29.7 PRKN LRRK2 GBA C19orf12
30 pick disease of brain 29.6 PRKN LRRK2 FUS
31 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 29.6 LRRK2 FUS FIG4
32 dentatorubral-pallidoluysian atrophy 29.5 PRKN FUS FMR1
33 dementia 29.5 PRKN MT-ATP6 LRRK2 LOC106627981 GBA FUS
34 peripheral nervous system disease 29.5 PRKN MT-ATP6 MPZ LRRK2 HARS1 FIG4
35 tooth disease 29.2 PRKN MT-ATP6 MPZ HARS1 FIG4
36 charcot-marie-tooth disease 29.2 PRKN MT-ATP6 MPZ HARS1 FIG4
37 optic nerve disease 28.9 PRKN MT-ATP6 C19orf12
38 primary orthostatic tremor 11.5
39 myopathy, congenital, with tremor 11.4
40 tremor, hereditary essential, 6 11.4
41 epilepsy, familial adult myoclonic, 5 11.4
42 epilepsy, familial adult myoclonic, 3 11.4
43 epilepsy, familial adult myoclonic, 2 11.4
44 epilepsy, familial adult myoclonic, 1 11.3
45 leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism 11.3
46 neurodegeneration, childhood-onset, with ataxia, tremor, optic atrophy, and cognitive decline 11.3
47 epilepsy, familial adult myoclonic, 4 11.3
48 epilepsy, familial adult myoclonic, 6 11.3
49 epilepsy, familial adult myoclonic, 7 11.3
50 polr3-related leukodystrophy 11.3

Graphical network of the top 20 diseases related to Tremor:



Diseases related to Tremor
Sources

Symptoms & Phenotypes for Tremor

About this section

GenomeRNAi Phenotypes related to Tremor according to GeneCards Suite gene sharing:

26 (show all 19)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-104 9.62 GBA
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-118 9.62 GBA
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-132 9.62 DRD3
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-137 9.62 DRD3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-151 9.62 GBA
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-159 9.62 DRD3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 9.62 DRD3
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-175 9.62 HARS1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.62 HARS1
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-34 9.62 GBA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-40 9.62 HARS1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-51 9.62 DRD3 GBA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-54 9.62 HARS1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-55 9.62 DRD3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-67 9.62 DRD3
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 9.62 GBA
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.62 GBA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-81 9.62 GBA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-85 9.62 DRD3
Sources

Drugs & Therapeutics for Tremor

About this section

Drugs for Tremor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
2
Propranolol Approved, Investigational Phase 4 525-66-6 4946
3
Memantine Approved, Investigational Phase 4 19982-08-2 4054
4
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
5
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
6
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
7
Imidazole Experimental, Investigational Phase 4 288-32-4 795
8 Anticonvulsants Phase 4
9 Psychotropic Drugs Phase 4
10 Anti-Anxiety Agents Phase 4
11 Dopamine Agents Phase 4
12 Antiparkinson Agents Phase 4
13 Adrenergic beta-Antagonists Phase 4
14 Anti-Arrhythmia Agents Phase 4
15 Vasodilator Agents Phase 4
16 Adrenergic Antagonists Phase 4
17 Antihypertensive Agents Phase 4
18 Dopamine agonists Phase 4
19 Anti-Infective Agents, Local Phase 4
20 Anti-Infective Agents Phase 4
21 Excitatory Amino Acid Antagonists Phase 4
22 Immunosuppressive Agents Phase 4
23 Immunologic Factors Phase 4
24 Calcineurin Inhibitors Phase 4
25
Topiramate Approved Phase 3 97240-79-4 5284627
26
Acetylcholine Approved, Investigational Phase 3 51-84-3 187
27
tannic acid Approved Phase 3 1401-55-4
28
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
29
Sodium oxybate Approved Phase 2, Phase 3 502-85-2 5360545
30
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
31
Ethanol Approved Phase 2, Phase 3 64-17-5 702
32 Hypoglycemic Agents Phase 3
33 Carbidopa, levodopa drug combination Phase 3
34 abobotulinumtoxinA Phase 3
35 Cholinergic Agents Phase 3
36 Botulinum Toxins, Type A Phase 3
37 Botulinum Toxins Phase 3
38 Anesthetics, General Phase 2, Phase 3
39 Anesthetics Phase 2, Phase 3
40 Anesthetics, Intravenous Phase 2, Phase 3
41 Antipsychotic Agents Phase 3
42
Levetiracetam Approved Phase 1, Phase 2 102767-28-2 441341
43
Sage Approved Phase 2
44
Dronabinol Approved, Illicit Phase 1, Phase 2 1972-08-3 16078
45
Zonisamide Approved, Investigational Phase 2 68291-97-4 5734
46 Strawberry Approved Phase 2
47
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
48
Levodopa Approved Phase 2 59-92-7 6047
49
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
50
Promethazine Approved, Investigational Phase 2 60-87-7 4927

Interventional clinical trials:

(show top 50) (show all 261)
# Name Status NCT ID Phase Drugs
1 A Multi-site, Double-blind, Randomized, Placebo-controlled, Crossover Study of Pregabalin (Lyrica, PGB) in the Treatment of Essential Tremor Completed NCT00584376 Phase 4 Pregabalin;Placebo
2 Effects of Dexmedetomidine vs Propofol on the Recordings of Deep Brain Activity (Local Field Potentials) Measured Through Implanted Stimulators Completed NCT02256319 Phase 4 Dexmedetomidine;Propofol
3 Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response Completed NCT02495883 Phase 4 Propranolol
4 Propranolol and Botulinum Toxin for Essential Vocal Tremor Completed NCT02111369 Phase 4 Propranolol
5 A Pilot Clinical Trial of Memantine for Essential Tremor Completed NCT00439699 Phase 4 Memantine
6 A Multicenter, Open-Label, Two-Arm Study to Evaluate the Impact of Using Wearable Devices in Addition to Standard Clinical Practice on Parkinson´s Subject Symptoms Management Completed NCT03103919 Phase 4 Rotigotine
7 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Oculopalatal Tremor: a Controled Open-label Study Completed NCT02466191 Phase 4 Memantine;Gabapentin
8 RECHARGE Sub-Study to the Implantable Systems Performance Registry (ISPR) Completed NCT00998660 Phase 4
9 A Placebo-controlled, Double-blind, Randomized, Cross Over Pilot Study of the Efficacy and Tolerability of Abobotulinum Toxin A (Dysport) as a Treatment for Task-dependent Upper Limb Tremor Recruiting NCT03136341 Phase 4 Abobotulinum toxin A
10 A Pilot Study to Evaluate Impact on Neurological Side Effects (Cognition, Memory, and Tremor) in Elderly (Age>65) Patients Recruiting NCT03461445 Phase 4 Envarsus;IR Tacrolimus
11 A Pilot Study of Stable Kidney Transplant Recipients Taking Tacrolimus With CNS Symptoms Switched to Envarsus Active, not recruiting NCT03270462 Phase 4 Envarsus XR
12 Atlas Predicted DBS Settings in Essential Tremor Suspended NCT02678429 Phase 4
13 A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Essential Tremor Completed NCT00236496 Phase 3 topiramate
14 CSP #468 Phase II - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease, Phase II Completed NCT01076452 Phase 3
15 CSP #468 Phase I - A Comparison of Best Medical Therapy and Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus for the Treatment of Parkinson's Disease Completed NCT00056563 Phase 3
16 Earlier Versus Later L-Dopa in Parkinson's Disease Completed NCT00004733 Phase 3 levodopa
17 Novel Therapies for Essential Tremor Completed NCT00018564 Phase 3 treatments for essential tremor
18 The Single Center, Phase III Clinical Trial to Evaluate the Efficacy and the Safety of [18F]FPCIT Positron Emission Tomography in Parkinson's Disease and Essential Tremor Patients Completed NCT00468078 Phase 3 F-18 FPCIT
19 Intravenous Dexmedetomidine for Treatment of Shivering During Cesarean Section Under Neuraxial Anesthesia: A Randomized Controlled Trial Completed NCT02384343 Phase 3 Dexmedetomidine;Normal saline
20 Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO) Completed NCT01438710 Phase 3 Prograf;LCP-Tacro
21 Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis Completed NCT01018485 Phase 3 Botulinum Toxin Type A
22 Diaphragmatic Breathing and Heart Rate Variability Training for Improving Hypertension in Fragile X Associated Tremor/Ataxia Completed NCT03816540 Phase 3
23 Evaluation of Botulinum Toxin Injection Efficacy in the Treatment of Head Essential Tremor by a Multi-center, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Recruiting NCT02555982 Phase 3 BOTOX ® 200 Unités;Placebo
24 Bilateral Essential Tremor Treatment With Magnetic Resonance-guided Focused Ultrasound Recruiting NCT04501484 Phase 2, Phase 3
25 A Multicentre, Phase 3, Clinical Study to Compare the Striatal Uptake of a Dopamine Transporter Radioligand, DaTSCAN™ Ioflupane (123I) Injection, After Intravenous Administration to Chinese Patients With a Diagnosis of Parkinson's Disease, Multiple System Atrophy, Progressive Supranuclear Palsy, or Essential Tremor and to Healthy Controls Recruiting NCT04193527 Phase 3 DaTSCAN™ Ioflupane (123I) Injection
26 Central Mechanisms and Treatment Response of Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor Recruiting NCT03292458 Phase 2, Phase 3 Sodium Oxybate
27 Bilateral Essential Tremor Treatment With Gamma Knife Not yet recruiting NCT04748640 Phase 2, Phase 3
28 Non-inferiority Study of the Molecular Imaging of Dopamine Transporters Using [123I]-FP/CIT-SPECT and [18F] LBT-999-PET to Distinguish Between Parkinson's Disease and Essential Tremor. Not yet recruiting NCT04265209 Phase 3 SPECT;PET
29 A 4 Week, Parallel-Design, Double-Blind, Placebo-Controlled Trial of Gabapentin in the Treatment of Neuroleptic-Induced Tremor: Clinical and Instrumental Ratings of Outcome. Terminated NCT00533455 Phase 3 Gabapentin
30 Efficacy of Pramipexole Extended Release in the Treatment of Essential Tremor: a Double-blind, Cross-over, Placebo-controlled Multicenter Study Withdrawn NCT01441284 Phase 3 pramipexole;placebo
31 Dexmedetomidine Effects on Microelectrode Recording in Deep Brain Stimulation Withdrawn NCT00608231 Phase 2, Phase 3 Dexmedetomidine Hydrochloride Infusion;Normal Saline
32 An Evaluation of Effectiveness and Toxicity of CyberKnife Based Functional Radiosurgery for Parkinson Disease Patients Suffering From Tremor and Its Implementation in Poland Unknown status NCT02406105 Phase 2 CyberKnife
33 Transcranial Static Magnetic Field Stimulation (tSMS) in Essential Tremor Unknown status NCT03780426 Phase 2
34 A Double-Blind, Cross-Over, Placebo-Controlled Efficacy and Tolerability Study of Perampanel and Essential Tremor Unknown status NCT02668146 Phase 2 Perampanel;Placebo
35 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Tremor Associated With Parkinson's Disease Unknown status NCT03436953 Phase 2 CX-8998;Placebo
36 Randomised Crossover Trial of Deep Brain Stimulation of Differential Posterior Subthalamic Area Regions in Parkinson's Disease and Tremor Unknown status NCT01945567 Phase 2
37 Efficacy of Levetiracetam in Patients With Essential Tremor Completed NCT00620165 Phase 1, Phase 2 levetiracetam;placebo
38 A Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Safety, Tolerability and Proof of Concept Study of ST101 for Essential Tremor Completed NCT01332695 Phase 2 ST101;Placebo
39 Effects of Octanoic Acid for Treatment of Essential Voice Tremor Completed NCT01864525 Phase 1, Phase 2 Octanoic acid;Inactive capsule
40 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response Completed NCT01961297 Phase 2 Sodium oxybate
41 Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor Completed NCT00102596 Phase 2 1-Octanol
42 Effect of Alcohol on Physiologic and Pathologic Tremors Completed NCT00001925 Phase 2 Alcohol
43 A Phase 2, Double-Blind, Placebo-controlled, Randomized Study Evaluating the Efficacy, Safety, and Tolerability of Sage-324 in the Treatment of Individuals With Essential Tremor Completed NCT04305275 Phase 2 SAGE-324;SAGE-324 Placebo
44 A Double-Blind, Cross-Over, Placebo- Controlled Efficacy and Tolerability Study of Oral Cannabidiol (CBD) and Tetrahydrocannabinol (THC) for Essential Tremor (ET). Completed NCT03805750 Phase 1, Phase 2 CBD/THC;Placebo oral capsule
45 A Randomized, Double Blind, Placebo-Controlled, Crossover, Proof of Concept Study to Evaluate the Effectiveness and Safety of Carisbamate in the Treatment of Essential Tremor Completed NCT00524056 Phase 2 Carisbamate;Placebo
46 A Phase 2a Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of CAD-1883 Oral Treatment in Adults With Essential Tremor Completed NCT03688685 Phase 2 CAD-1883
47 Multiple-dose, Double-blind, Placebo-controlled, Crossover Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Sodium Oxybate (Xyrem) in Subjects With Moderate to Severe Essential Tremor Completed NCT00598078 Phase 2 Sodium Oxybate;Sodium Oxybate
48 Double-Blind, Placebo Controlled Pilot-Study of Octanoic Acid in Essential Tremor Completed NCT00848172 Phase 1, Phase 2 Octanoic Acid;Placebo
49 A Double-blind, Placebo-controlled, Two-Period Crossover Proof-of-Concept Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-547 Injection in the Treatment of Patients With Essential Tremor Completed NCT02277106 Phase 2 SAGE-547;Placebo
50 Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy and Safety of NT 201 in the Unilateral Treatment of Essential Tremor of the Upper Limb Completed NCT02207946 Phase 2 IncobotulinumtoxinA;Placebo

Search NIH Clinical Center for Tremor

Sources

Genetic Tests for Tremor

About this section

Genetic tests related to Tremor:

# Genetic test Affiliating Genes
1 Tremor 29
Sources

Anatomical Context for Tremor

About this section

MalaCards organs/tissues related to Tremor:

40
Brain, Subthalamic Nucleus, Thalamus, Cortex, Cerebellum, Tongue, Eye
Sources

Publications for Tremor

About this section

Articles related to Tremor:

(show top 50) (show all 23105)
# Title Authors PMID Year
1
Imaging Tremor Quantification for Neurological Disease Diagnosis. 61 42
33266481 2020
2
Subthalamic beta-targeted neurofeedback speeds up movement initiation but increases tremor in Parkinsonian patients. 42 61
33205752 2020
3
Parkinson's Disease Tremor Detection in the Wild Using Wearable Accelerometers. 61 42
33066691 2020
4
Whole-genome sequencing of patients with rare diseases in a national health system. 6
32581362 2020
5
SARS-CoV-2 associated viral encephalitis with mortality outcome. 61
33654659 2021
6
Efficacy of short-term multidisciplinary intensive rehabilitation in patients with different Parkinson's disease motor subtypes: a prospective pilot study with 3-month follow-up. 61
33318414 2021
7
Preserved noradrenergic function in Parkinson's disease patients with rest tremor. 61
33549722 2021
8
Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. 61
33450346 2021
9
Evaluation of Pseudorandom Sonications for Reducing Cavitation With a Clinical Neurosurgery HIFU Device. 61
33166253 2021
10
Abnormal cerebellar function and tremor in a mouse model for non-manifesting partially penetrant dystonia type 6. 61
33369735 2021
11
Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease. 61
33508286 2021
12
A selective delta opioid receptor agonist SNC80, but not KNT-127, induced tremor-like behaviors via hippocampal glutamatergic system in mice. 61
33516811 2021
13
Cerebello-Cortical Control of Tremor Rhythm and Amplitude in Parkinson's Disease. 61
33792966 2021
14
Tremors: A concept analysis. 61
33797860 2021
15
Normative vocal acoustic parameters for preschool and elementary school Egyptian children. 61
33667836 2021
16
A case of Anti-LGi1 antibody positive autoimmune epilepsy following deep brain stimulator implantation for essential tremor. 61
33567372 2021
17
Premutations in the FMR1 gene in Serbian patients with undetermined tremor, ataxia and parkinsonism. 61
33403926 2021
18
The Effects of Dual Task Cognitive Interference and Fast-Paced Walking on Gait, Turns, and Falls in Men and Women with FXTAS. 61
33118140 2021
19
3-Hz Postural Tremor in MSA-C and SCA: Revisiting an Old but Underestimated Cerebellar Sign by Posturography. 61
33164129 2021
20
Primary Hypoparathyroidism and Recurring Hypocalcemia in a Quarter Horse Gelding-A Case Report. 61
33781415 2021
21
Manganese and copper levels in patients with primary biliary cirrhosis and primary sclerosing cholangitis. 61
33428478 2021
22
Rapid-onset dystonia-parkinsonism with ATP1A3 mutation and left lower limb paroxysmal dystonia. 61
33451880 2021
23
Emerging concepts on bradykinesia in non-parkinsonian conditions. 61
33793037 2021
24
Delayed-onset motor aphasia succeeds Holmes' tremor and neuropathic pain after left thalamic hemorrhage. 61
33735755 2021
25
Abnormal movements in hospitalized COVID-19 patients: A case series. 61
33676146 2021
26
Thyroid hormone levels and structural parameters of thyroid homeostasis are correlated with motor subtype and disease severity in euthyroid patients with Parkinson's disease. 61
32186220 2021
27
Calpain activity in plasma of patients with essential tremor and Parkinson's disease: a pilot study. 61
33729106 2021
28
Altered spontaneous brain activity in essential tremor with and without resting tremor: a resting-state fMRI study. 61
32661843 2021
29
Increased Purkinje Cell Complex Spike and Deep Cerebellar Nucleus Synchrony as a Potential Basis for Syndromic Essential Tremor. A Review and Synthesis of the Literature. 61
33048308 2021
30
REM sleep behaviour disorder in essential tremor: A polysomnographic study. 61
32323893 2021
31
Laboratory testing for fragile X, 2021 revision: a technical standard of the American College of Medical Genetics and Genomics (ACMG). 61
33795824 2021
32
A novel PNPLA6 mutation in a Turkish family with intractable Holmes tremor and spastic ataxia. 61
33210227 2021
33
Tremor-Dominant Cervical Dystonia: a Cerebellar Syndrome. 61
33161481 2021
34
Characterizing the protracted neurobiological and neuroanatomical effects of paraquat in a murine model of Parkinson's disease. 61
33450723 2021
35
SCYL1 disease and liver transplantation diagnosed by reanalysis of exome sequencing and deletion/duplication analysis of SCYL1. 61
33442927 2021
36
Valproate-induced rest tremor and parkinsonism. 61
31721077 2021
37
Primary care providers perform more neurologic visits than neurologists among Medicare beneficiaries. 61
32754960 2021
38
Genetic characterization of a cohort with familial parkinsonism and cognitive-behavioral syndrome: A Next Generation Sequencing study. 61
33601107 2021
39
First symptom guides diagnosis and prognosis in neurodegenerative diseases-a retrospective study of autopsy proven cases. 61
33662165 2021
40
Clinical presentation and evolution of Xia-Gibbs syndrome due to p.Gly375ArgfsTer3 variant in a patient from DR Congo (Central Africa). 61
33372375 2021
41
Effectiveness and safety of electroacupuncture in treating Parkinson disease: A protocol for systematic review and meta-analyses. 61
33725902 2021
42
Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson's Disease. 61
33202088 2021
43
Spinal astroglial cannabinoid receptors control pathological tremor. 61
33737752 2021
44
Kampo Medicine for Essential Voice Tremor. 61
33711821 2021
45
The Brain Connectome after Gamma Knife Radiosurgery of the Ventro-Intermediate Nucleus for Tremor: Marseille-Lausanne Radiobiology Study Protocol. 61
33684913 2021
46
Increased structural connectivity of thalamic stimulation sites to motor cortex relates to tremor suppression. 61
33773164 2021
47
Speech Function Following Deep Brain Stimulation of the Caudal Zona Incerta: Effects of Habitual and High-Amplitude Stimulation. 61
33647213 2021
48
Holmes tremor in a monocentric series of resected brainstem cavernomas. 61
33753127 2021
49
Therapeutic Applications of Botulinum Neurotoxin for Autonomic Symptoms in Parkinson's Disease: An Updated Review. 61
33808714 2021
50
Impact of motor subtype on non-motor symptoms and fall-related features in patients with early Parkinson's disease. 61
33780137 2021
Sources

Variations for Tremor

About this section

ClinVar genetic disease variations for Tremor:

6 (show all 18)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 overlap with 3 genes NC_000006.11:g.(117961791_117961792)_(118280043_118280044)del Deletion Pathogenic 180225 GRCh37: 6:117961791-118280044
GRCh38: 6:117640628-117958881
2 overlap with 2 genes NC_000006.11:g.(117971549_117971550)_(118218719_118218720)del Deletion Pathogenic 180226 GRCh37: 6:117971549-118218720
GRCh38: 6:117650386-117897557
3 overlap with 24 genes NC_000006.11:g.(116681080_116735056)_(119687719_119775014)del Deletion Pathogenic 180227 GRCh37: 6:116681080-119775014
GRCh38:
4 C19orf12 NM_001031726.3(C19orf12):c.424A>G (p.Lys142Glu) SNV Pathogenic 31158 rs146170087 GRCh37: 19:30193654-30193654
GRCh38: 19:29702747-29702747
5 HARS1 NM_002109.6(HARS1):c.616G>T (p.Asp206Tyr) SNV Pathogenic 804285 rs1131040 GRCh37: 5:140057507-140057507
GRCh38: 5:140677922-140677922
6 HARS1 NM_002109.6(HARS1):c.730delG Deletion Pathogenic 804286 rs1581505917 GRCh37: 5:140057005-140057005
GRCh38: 5:140677420-140677420
7 C19orf12 NM_001031726.3(C19orf12):c.205G>A (p.Gly69Arg) SNV Pathogenic 31157 rs515726205 GRCh37: 19:30193873-30193873
GRCh38: 19:29702966-29702966
8 LOC106627981 , GBA NM_000157.4(GBA):c.1093G>A (p.Glu365Lys) SNV risk factor 199044 rs2230288 GRCh37: 1:155206167-155206167
GRCh38: 1:155236376-155236376
9 TMEM67 NM_153704.6(TMEM67):c.1843T>C (p.Cys615Arg) SNV Likely pathogenic 1383 rs201893408 GRCh37: 8:94808198-94808198
GRCh38: 8:93795970-93795970
10 TMEM67 NM_153704.6(TMEM67):c.1321C>T (p.Arg441Cys) SNV Likely pathogenic 217725 rs752362727 GRCh37: 8:94798483-94798483
GRCh38: 8:93786255-93786255
11 MT-ATP6 NC_012920.1:m.9032T>C SNV Likely pathogenic 693061 rs1603221994 GRCh37: MT:9032-9032
GRCh38: MT:9032-9032
12 FIG4 NM_014845.5(FIG4):c.904G>A (p.Glu302Lys) SNV Likely pathogenic 156015 rs587777714 GRCh37: 6:110064340-110064340
GRCh38: 6:109743137-109743137
13 MPZ NM_000530.8(MPZ):c.699T>G (p.Ser233Arg) SNV Likely pathogenic 374017 rs1057518839 GRCh37: 1:161275714-161275714
GRCh38: 1:161305924-161305924
14 TBC1D24 NM_001199107.2(TBC1D24):c.920A>G (p.Asn307Ser) SNV Uncertain significance 583333 rs761934676 GRCh37: 16:2547069-2547069
GRCh38: 16:2497068-2497068
15 SYNE1 NM_182961.4(SYNE1):c.25015G>T (p.Gly8339Cys) SNV Uncertain significance 983391 GRCh37: 6:152464862-152464862
GRCh38: 6:152143727-152143727
16 GLI2 NM_001374353.1(GLI2):c.2593A>T (p.Thr865Ser) SNV Uncertain significance 523482 rs1332140763 GRCh37: 2:121746134-121746134
GRCh38: 2:120988558-120988558
17 CACNA1H NM_021098.3(CACNA1H):c.6884C>T (p.Ser2295Phe) SNV Uncertain significance 523531 rs772718469 GRCh37: 16:1270816-1270816
GRCh38: 16:1220816-1220816
18 ADGRV1 NM_032119.4(ADGRV1):c.5188A>T (p.Ile1730Phe) SNV Uncertain significance 523543 rs1554079046 GRCh37: 5:89971137-89971137
GRCh38: 5:90675320-90675320

Copy number variations for Tremor from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 247217 9 129375646 129461836 Deletion NIBAN2 Tremor
2 247222 9 129375646 129461836 Deletion STXBP1 Tremor
Sources

Expression for Tremor

About this section
Search GEO for disease gene expression data for Tremor.
Sources

Pathways for Tremor

About this section

Pathways related to Tremor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Neuroscience 4
11.46 PRKN LRRK2 FMR1 CNTN2
Sources

GO Terms for Tremor

About this section

Cellular components related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.43 PRKN MPZ LRRK2 FMR1 DRD3 CNTN2
2 neuron projection GO:0043005 9.02 TENM4 PRKN LRRK2 FMR1 CNTN2

Biological processes related to Tremor according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 response to oxidative stress GO:0006979 9.77 PRKN LRRK2 C19orf12
2 mitochondrion organization GO:0007005 9.7 PRKN LRRK2 GBA
3 locomotory behavior GO:0007626 9.67 PRKN FIG4 DRD3
4 positive regulation of proteasomal ubiquitin-dependent protein catabolic process GO:0032436 9.63 PRKN LRRK2 GBA
5 regulation of neurotransmitter secretion GO:0046928 9.58 PRKN FMR1
6 negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway GO:1902236 9.58 PRKN LRRK2
7 determination of adult lifespan GO:0008340 9.57 LRRK2 GBA
8 positive regulation of proteasomal protein catabolic process GO:1901800 9.56 PRKN FMR1
9 dopamine metabolic process GO:0042417 9.55 PRKN DRD3
10 cellular response to dopamine GO:1903351 9.54 PRKN LRRK2
11 learning GO:0007612 9.54 PRKN DRD3 CNTN2
12 synaptic transmission, dopaminergic GO:0001963 9.51 PRKN DRD3
13 negative regulation of neuron death GO:1901215 9.5 PRKN LRRK2 GBA
14 negative regulation of voltage-gated calcium channel activity GO:1901386 9.48 FMR1 DRD3
15 cellular response to manganese ion GO:0071287 9.43 PRKN LRRK2
16 regulation of locomotion GO:0040012 9.4 LRRK2 DRD3
17 protein localization to mitochondrion GO:0070585 9.26 PRKN LRRK2
18 positive regulation of dopamine receptor signaling pathway GO:0060161 9.16 LRRK2 DRD3
19 autophagy GO:0006914 9.02 PRKN LRRK2 GBA DRD3 C19orf12
20 regulation of synaptic vesicle transport GO:1902803 8.96 PRKN LRRK2

Molecular functions related to Tremor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 TENM4 PRKN LRRK2 HARS1 FUS FMR1
Sources

Sources for Tremor

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....